Logo

Abbott Presents Results of TriClip Device and Navitor TAVI System for Tricuspid Regurgitation & Aortic Stenosis at EuroPCR 2022

Share this
Abbott Presents Results of TriClip Device and Navitor TAVI System for Tricuspid Regurgitation & Aortic Stenosis at EuroPCR 2022

Abbott Presents Results of TriClip Device and Navitor TAVI System for Tricuspid Regurgitation & Aortic Stenosis at EuroPCR 2022

Shots:

  • The 30-day results from the TriClip (bRIGHT) study of TriClip & TriClip G4 TEER systems showed a high implant success rate (98%), TR reduction (71% vs 3% as baseline), 78% achieved NYHA Functional Class I/II, improvement by 57% from a baseline of 21% & 18-point improvement in KCCQ score
  • The 1yr. results of the Navitor TAVI system showed the safety, effectiveness & durable response for sev. AS, 97.5% high procedural success rate, high rate of no/trace PVL (70.2%) & low rate of mild PVL & all-cause mortality (28.8% & 4.2%) indicating the active sealing cuff & effective in mitigating PVL
  • The company highlighted the new results from the (EXPAND) study for MitraClip in HF patients with MR  & Amplatzer Amulet for AF

Ref: Abbott | Image: Abbott

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions